DK1499736T3 - Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer - Google Patents

Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer

Info

Publication number
DK1499736T3
DK1499736T3 DK03747185T DK03747185T DK1499736T3 DK 1499736 T3 DK1499736 T3 DK 1499736T3 DK 03747185 T DK03747185 T DK 03747185T DK 03747185 T DK03747185 T DK 03747185T DK 1499736 T3 DK1499736 T3 DK 1499736T3
Authority
DK
Denmark
Prior art keywords
vectors
pseudotyped
medium
lentoviral
producer cell
Prior art date
Application number
DK03747185T
Other languages
Danish (da)
English (en)
Inventor
Francios-Loic Cosset
Virginie Sandrin
Bertrand Boson
Didier Negre
Didier Trono
Patrick Salmon
Original Assignee
Inst Nat Sante Rech Med
Inst Clayton De La Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Inst Clayton De La Rech filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1499736T3 publication Critical patent/DK1499736T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
DK03747185T 2002-04-26 2003-04-25 Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer DK1499736T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37565402P 2002-04-26 2002-04-26
PCT/IB2003/001597 WO2003091442A1 (fr) 2002-04-26 2003-04-25 Glycoproteines chimeriques ameliorees et vecteurs lentiviraux pseudotypes ameliores

Publications (1)

Publication Number Publication Date
DK1499736T3 true DK1499736T3 (da) 2009-06-08

Family

ID=29270681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03747185T DK1499736T3 (da) 2002-04-26 2003-04-25 Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer

Country Status (13)

Country Link
US (2) US8338168B2 (fr)
EP (1) EP1499736B1 (fr)
JP (1) JP4343708B2 (fr)
KR (1) KR101002955B1 (fr)
CN (1) CN100340668C (fr)
AT (1) ATE424464T1 (fr)
AU (1) AU2003226598A1 (fr)
CA (1) CA2484166C (fr)
DE (1) DE60326444D1 (fr)
DK (1) DK1499736T3 (fr)
ES (1) ES2326217T3 (fr)
HK (1) HK1073479A1 (fr)
WO (1) WO2003091442A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019144A1 (fr) * 2007-07-23 2009-01-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Particules-vecteur pour cibler les cellules CD34+
PL2456786T5 (pl) * 2009-07-24 2017-10-31 Immune Design Corp Wektory lentiwirusowe pseudotypowane glikoproteiną otoczki wirusa sindbis
EP3173096A1 (fr) 2011-04-06 2017-05-31 Biovaxim Limited Compositions pharmaceutiques pour prévenir et/ou traiter une maladie vih chez l'homme
RU2618864C2 (ru) * 2011-09-29 2017-05-11 Энститю Насьональ Де Ля Сантэ Э Дэ Ля Решерш Медикаль (Инсерм) ЛЕНТИВИРУСНЫЕ ВЕКТОРЫ, ПСЕВДОТИПИРОВАННЫЕ МУТАНТНЫМИ BaEV ГЛИКОПРОТЕИНАМИ
DK2790737T3 (en) * 2011-12-12 2019-03-18 Childrens Hospital Philadelphia COMMERCIAL LARGE SCALE LENTIVIRUS VECTOR-MANUFACTURING SYSTEM AND VECTORS MADE THEREOF
US20150203540A1 (en) * 2012-07-27 2015-07-23 The Trustees Of The University Of Pennsylvania Cytoplasmic Tail Modifications to Boost Surface Expression and Immunogenicity of Envelope Glycoproteins
BR112016014881B1 (pt) * 2013-12-24 2023-03-28 Kling Biotherapeutics B.V Métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, uso in vitro de pelo menos uma parte funcional do domínio extracelular de uma proteína galv e de um veículo de dispensa de genes
WO2016041080A1 (fr) * 2014-09-18 2016-03-24 Université de Montréal Composés et procédé pour l'accroissement du transfert de gènes viraux vers des cellules hématopoïétiques humaines
US20220204946A1 (en) * 2019-05-20 2022-06-30 Instituto De Biologia Experimental E Technológica (Ibet) Modified envelope glycoproteins for retroviridae viral vector pseudotyping and process for obtaining it
EP4086352A1 (fr) 2021-05-07 2022-11-09 Medizinische Hochschule Hannover Glycoprotéines pour le pseudotypage de particules à vecteur rétroviral

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
EP0266032A1 (fr) 1986-08-29 1988-05-04 Beecham Group Plc Enzyme fibrinolytique modifiée
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
DE4204650C1 (fr) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
CA2288328A1 (fr) * 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Vecteurs de transfert de gene comportant un lentivirus
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6849454B2 (en) * 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles

Also Published As

Publication number Publication date
CN1659284A (zh) 2005-08-24
CA2484166A1 (fr) 2003-11-06
WO2003091442A1 (fr) 2003-11-06
KR101002955B1 (ko) 2010-12-21
JP2005523706A (ja) 2005-08-11
CN100340668C (zh) 2007-10-03
HK1073479A1 (en) 2005-10-07
AU2003226598A8 (en) 2003-11-10
JP4343708B2 (ja) 2009-10-14
US9090908B2 (en) 2015-07-28
ES2326217T3 (es) 2009-10-05
DE60326444D1 (de) 2009-04-16
AU2003226598A1 (en) 2003-11-10
ATE424464T1 (de) 2009-03-15
US8338168B2 (en) 2012-12-25
EP1499736A1 (fr) 2005-01-26
CA2484166C (fr) 2011-11-29
KR20050008697A (ko) 2005-01-21
US20060257366A1 (en) 2006-11-16
EP1499736B1 (fr) 2009-03-04
US20140004089A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
HK1073479A1 (en) Improved chimeric glycoproteins and pseudotyped lentiviral vectors
CA2442679A1 (fr) Procede de production secretoire de proteines
AU2220800A (en) Compositions and methods for packaging of alphavirus vectors
MY102902A (en) Lymphokine production and purification.
DK0842279T3 (da) Hjælpevirus til fremstilling af rekombinante virusvektorer
ATE454039T1 (de) Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung
ATE197608T1 (de) Signalsequenzen für die secretion heterologer proteine von hefe
CA2498668A1 (fr) Production de plantes a tolerance amelioree vis-a-vis de la secheresse
EP1029918A4 (fr) Recepteur de lymphocyte t tueur reconnaissant le vih
AU2003294397A8 (en) Promoter variants for expressing genes in a fungal cell
DK1546302T3 (da) Fremgangsmåder til fremstilling af pattedyrs-trypsiner
EP1262551A3 (fr) Gène codant pour la sorbitol déshydrogénase, ADN recombinant, et procédé de production de la sorbitol déshydrogénase
EP0475182A3 (en) Method for protein synthesis using cks fusion proteins
KR102121817B1 (ko) Crispr 편집 기술을 이용한 재조합 항원을 발현시키는 벡터 및 이를 동시에 다중 삽입시키는 방법
EP1163844A4 (fr) Mollusque transgenique et son procede de creation
AU2001289621A1 (en) Promoters for gene expression in caryopses of plants
MX2023009213A (es) Construccion y aplicacion de un mutante de la omega-transaminasa reversible enantioselectivamente.
MXPA05008221A (es) Antigenos recombinantes del virus de la hepatitis a obtenidos en celulas vegetales.
CA2354844A1 (fr) Vecteurs du virus d'epstein-barr a segment terminal a repetition
NZ596925A (en) Polymer particles and uses thereof
DK0959130T3 (da) Kloning og udtrykkelse af nyt glucoamylasegen fra Endomyces fibuliger